Neuromyelitis Optica (NMO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neuromyelitis Optica (NMO) Market Outlook

Thelansis’s “Neuromyelitis Optica (NMO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica (NMO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neuromyelitis Optica (NMO) Overview

Neuromyelitis optica (NMO), also known as Devic syndrome, manifests as a clinical syndrome characterized by recurrent acute optic neuritis and transverse myelitis. In the majority of patients, NMO is driven by pathogenic serum IgG autoantibodies targeting aquaporin 4 (AQP4), which happens to be the most prevalent water-channel protein within the central nervous system (CNS). In more than 80% of cases, NMO is a result of the presence of pathogenic IgG autoantibodies directed against aquaporin 4 (AQP4-IgG), the predominant water channel protein in the CNS. Roughly 10–40% of individuals diagnosed with NMO who do not possess AQP4-IgG instead have IgG autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG). Notably, MOG-IgG is also detected in a subgroup of patients, primarily children, with acute disseminated encephalomyelitis (ADEM). The most prominent risk factor for NMO is gender, with a strong association observed in females, particularly in those with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD). NMO can manifest at any age, with a median age at onset of 40 years for AQP4-IgG-positive patients and 31 years for MOG-IgG-positive patients. It is more prevalent in women than men, especially among those with AQP4-IgG (male-to-female ratio ranging from 1:9 to 1:10). This gender discrepancy is less pronounced in patients with seronegative NMO and those with MOG-IgG. The management and treatment of NMO/NMOSD involve various strategies, including addressing symptoms, managing acute relapses, and implementing long-term maintenance through immunosuppressive therapies. Symptomatic therapy encompasses the treatment of pain, fatigue, bowel/bladder issues, cognitive deficits, sexual dysfunction, and muscle spasms. Acute relapse management includes corticosteroid therapy and plasma exchange (PLEX). However, approximately 90% of patients may eventually experience relapses and/or develop permanent disabilities. Consequently, long-term symptom management with immunotherapy is crucial in NMO/NMOSD due to its association with relapse-related disability, unfavorable prognosis, and high mortality risk in untreated individuals. The FDA has granted approval to three drugs for NMO relapse treatment in adults: Eculizumab (Soliris, Elizaria), Satralizumab (Enspryng), and Inebilizumab (Uplizna).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: